JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 12.74 Billion KRW | 22.02% |
| 2022 | 10.44 Billion KRW | 28.0% |
| 2021 | 8.15 Billion KRW | 35.32% |
| 2020 | 6.02 Billion KRW | 199.08% |
| 2019 | 2.01 Billion KRW | -21.11% |
| 2018 | 2.55 Billion KRW | 31.48% |
| 2017 | 1.94 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 17.06 Billion KRW | 20.16% |
| 2024 Q1 | 14.2 Billion KRW | 11.49% |
| 2023 Q1 | 12.4 Billion KRW | 18.79% |
| 2023 FY | 12.74 Billion KRW | 22.02% |
| 2023 Q4 | 12.74 Billion KRW | 3.51% |
| 2023 Q3 | 12.3 Billion KRW | 7.68% |
| 2023 Q2 | 11.43 Billion KRW | -7.84% |
| 2022 Q4 | 10.44 Billion KRW | 13.15% |
| 2022 Q3 | 9.22 Billion KRW | 12.19% |
| 2022 Q2 | 8.22 Billion KRW | 10.45% |
| 2022 Q1 | 7.44 Billion KRW | -8.7% |
| 2022 FY | 10.44 Billion KRW | 28.0% |
| 2021 Q2 | 8.05 Billion KRW | 5.18% |
| 2021 Q4 | 8.15 Billion KRW | 6.64% |
| 2021 FY | 8.15 Billion KRW | 35.32% |
| 2021 Q1 | 7.66 Billion KRW | 27.11% |
| 2021 Q3 | 7.64 Billion KRW | -5.09% |
| 2020 Q1 | 2.13 Billion KRW | 5.91% |
| 2020 FY | 6.02 Billion KRW | 199.08% |
| 2020 Q3 | 6.44 Billion KRW | -0.28% |
| 2020 Q4 | 6.02 Billion KRW | -6.51% |
| 2020 Q2 | 6.46 Billion KRW | 202.91% |
| 2019 Q4 | 2.01 Billion KRW | 0.0% |
| 2019 FY | 2.01 Billion KRW | -21.11% |
| 2019 Q3 | - KRW | 0.0% |
| 2019 Q1 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | 2.55 Billion KRW | 31.48% |
| 2017 FY | 1.94 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Co., Ltd. | 11.42 Billion KRW | -11.552% |
| iNtRON Biotechnology, Inc. | 1.01 Billion KRW | -1160.099% |
| BINEX Co., Ltd. | 28.26 Billion KRW | 54.918% |
| Bioneer Corporation | 41.35 Billion KRW | 69.191% |
| Anterogen.Co.,Ltd. | 1.91 Billion KRW | -566.887% |
| MEDIPOST Co., Ltd. | 14.51 Billion KRW | 12.234% |
| CrystalGenomics, Inc. | 1.55 Billion USD | -719.461% |
| Helixmith Co., Ltd | 914.11 Million KRW | -1293.799% |
| Chabiotech Co.,Ltd. | 34.11 Billion KRW | 62.655% |
| Medy-Tox Inc. | 59.61 Billion KRW | 78.629% |
| Peptron, Inc. | 172.18 Million KRW | -7299.447% |
| Amicogen, Inc. | 46.83 Billion KRW | 72.798% |
| Genexine, Inc. | 3.8 Billion KRW | -234.676% |
| HLB Therapeutics Co.,Ltd. | 5.33 Billion KRW | -138.781% |
| LegoChem Biosciences, Inc. | 196.83 Million KRW | -6372.91% |
| ALTEOGEN Inc. | 1.06 Billion KRW | -1092.568% |
| PharmaResearch Co., Ltd. | 50.23 Billion KRW | 74.636% |
| SillaJen, Inc. | 1.21 Billion KRW | -950.689% |
| OliX Pharmaceuticals,Inc | 468.4 Million KRW | -2620.039% |
| Genomictree Inc. | 496.53 Million KRW | -2465.983% |
| MedPacto, Inc. | 620.00 KRW | -2054985759.194% |
| D&D Pharmatech | 3.45 Billion KRW | -269.278% |
| EASY BIO,Inc. | 25.93 Billion KRW | 50.88% |
| GI Innovation, Inc. | - KRW | -Infinity% |